New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
10:40 EDTCTAS, SNY, SFLY, WEN, AOLHigh option volume stocks: CTAS SNY SFLY WEN AOL
News For CTAS;SNY;SFLY;WEN;AOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 28, 2014
09:20 EDTSNYOn The Fly: Pre-market Movers
Subscribe for More Information
05:40 EDTSNYSanofi reports Q3 business EPS EUR 1.47 vs. EUR 1.36 last year
Subscribe for More Information
October 27, 2014
10:17 EDTWENWendy's price target lowered to $9 from $10 at RBC Capital
RBC Capital lowered Wendy's price target to $10 and reduced estimates given the lack of success with its recent pork platform and value messaging by competitors. Share are Sector Perform rated.
07:23 EDTSNYAmerican College of Surgeons holds a conference
Subscribe for More Information
07:21 EDTSNYSanofi board explains CEO development not included in meeting, Reuters says
Subscribe for More Information
October 22, 2014
10:09 EDTAOLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AOL (AOL) upgraded to Buy from Hold at Evercore... ARM Holdings (ARMH) upgraded to Buy from Neutral at UBS... American Assets Trust (AAT) upgraded to Buy from Hold at MLV & Co.... American Midstream Partners (AMID) upgraded to Buy from Neutral at Ladenburg... BancorpSouth (BXS) upgraded to Neutral from Underweight at JPMorgan... Chesapeake (CHK) upgraded at UBS... Chuy's (CHUY) upgraded to Buy from Hold at Stifel... Dean Foods (DF) upgraded to Overweight from Equal Weight at Morgan Stanley... East West Bancorp (EWBC) upgraded at BMO Capital... El Paso Electric (EE) upgraded to Buy from Neutral at Ladenburg... Generac (GNRC) upgraded to Buy from Hold at KeyBanc... Gold Fields (GFI) upgraded to Overweight from Neutral at HSBC... Harmony Gold (HMY) upgraded to Neutral from Underweight at HSBC... Hess Corp. (HES) upgraded to Buy from Neutral at UBS... Hovnanian (HOV) upgraded to Market Perform from Underperform at JMP Securities... Intuitive Surgical (ISRG) upgraded to Buy from Neutral at BTIG... OMV AG (OMVKY) upgraded to Neutral from Underperform at Credit Suisse... Seaspan (SSW) upgraded to Neutral from Underperform at Credit Suisse... Sibanye Gold (SBGL) upgraded to Neutral from Underweight at HSBC... Smith & Nephew (SNN) upgraded to Overweight from Equal Weight at Barclays... Southwestern Energy (SWN) upgraded to Buy from Hold at Maxim... Steel Dynamics (STLD) upgraded to Outperform from Neutral at Macquarie... Steris (STE) upgraded to Strong Buy from Market Perform at Raymond James... Tesoro Logistics (TLLP) upgraded to Strong Buy from Outperform at Raymond James... Texas Instruments (TXN) upgraded to Outperform from Market Perform at Bernstein... Twitter (TWTR) upgraded to Hold from Sell at Hudson Square... Vanguard Natural (VNR) upgraded to Buy from Hold at Wunderlich... Volaris (VLRS) upgraded to Buy from Hold at Deutsche Bank... Wilshire Bancorp (WIBC) upgraded to Outperform from Neutral at Macquarie... Yahoo (YHOO) upgraded to Outperform from Market Perform at FBR Capital.
07:35 EDTSNYCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
06:30 EDTAOLAOL upgraded to Buy from Hold at Evercore
Subscribe for More Information
October 21, 2014
13:27 EDTAOLEarnings Preview: Yahoo expected to unveil turnaround plan with Q3 results
Yahoo (YHOO) is expected to report third quarter earnings after the market close on Tuesday, October 21 with a conference call scheduled for 5:00 pm ET. Yahoo is a digital media company that provides properties and services such as Yahoo! Search and Yahoo! News. EXPECTATIONS: Analysts are looking for EPS of 30c on revenue of $1.04B. The consensus range is 18c-38c for EPS, and $1.02B-$1.06B for revenue, according to First Call. LAST QUARTER: Yahoo reported Q2 EPS 37c against estimates of 38c on revenue ex-tac of $1.04B against estimates of $1.08B. It reported Q2 price-per-ad was down 24%, Q2 Display revenue down 7% and Search revenue up 6%. The company gave Q3 revenue ex-tac guidance of $1.02B-$1.06B. After releasing its Q2 results, CEO Marissa Mayer said the company was "not satisfied" with the results, with display remaining an area of investment and transition. NEWS: In the past quarter, Alibaba (BABA) opened to the larges IPO in U.S. history. The Wall Street Journal reported that Yahoo's core business was cut in half to $6.8B after Alibaba's first day of trading. Yahoo made $5.1B in cash from the sale of shares in Alibaba's IPO and its remaining stake is valued at about $23.4B.In late September, activist investor Starboard Value urged Yahoo to explore a strategic combination with AOL (AOL), believing a merger could create synergies of up to $1B. CEO Marissa Mayer is expected to unveil her turnaround plan at the earnings call today that could include cost-cutting efforts and its M&A strategy, according to the Wall Street Journal. Yahoo also confirmed that a security breach in Q3 compromised servers, but the hack did not disclose consumer data. The company acquired several companies in past few months, including Flurry, Zofari, ClarityRay, Luminate, and Bookdpad. A WSJ reports also said the company is in talks to invest in Snapchat. STREET RESEARCH: Following the Alibaba IPO, Yahoo was downgraded at Bernstein, BofA/Merrill and RBC Capital because it was unclear whether Yahoo's stock can advance meaningfully and the company was no longer the best way to gain Alibaba exposure. RBC Capital said the risk/reward is less attractive, and it does not see a turnaround in Yahoo's core fundamentals. BGC Financial, however, upgraded the company and said the company's remaining assets should get monetized in a more tax efficient manner. PRICE ACTION: Yahoo shares have risen $4.29, or more than 12%, since the first day of trading following the company's Q2 report. In Tuesday midday trading ahead of Q3 report, Yahoo shares are trading up nearly 2%.
08:17 EDTCTASCintas board approves increased annual dividend of 85c, special dividend
Subscribe for More Information
07:06 EDTSNYFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:44 EDTSNYActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
09:52 EDTAOLArmstrong says AOL will not merge with Yahoo, VentureBeat reports
AOL CEO Tim Armstrong said "no" when asked if his company will merge with Yahoo (YHOO), VentureBeat reports, citing a fireside chat with Armstrong at the TechCrunch Disrupt in Europe. Reference Link
09:49 EDTAOLAOL in early talks to spin off CrunchBase, TechCrunch reports
Subscribe for More Information
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:19 EDTSNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:10 EDTSNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTSNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
09:06 EDTSNYAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use